Vancouver, British Columbia – October 23, 2025 – Pangea Natural Foods Inc. (CSE:PNGA) (OTC:PNGAF) (“Pangea” or the “Company”) announced today that its wholly-owned subsidiary, Amino Innovations, has established a strategic scientific collaboration with two globally recognized pharmaceutical scientists, Dr. Neal Davies and Dr. Raimar Loebenberg. This partnership aims to expedite the research, validation, and development of sophisticated non-injectable peptide delivery systems for use in consumer wellness products.
Drs. Davies and Loebenberg, both senior professors within the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences, will contribute their expertise in formulation and validation. This will be facilitated through a Research Services Agreement, granting access to the University’s cutting-edge Drug Development and Innovation Centre (DDIC), including its facilities, staff, and pharmaceutical testing platforms.
Scope of Collaboration
The collaboration is designed to enable Amino Innovations to set a new standard for precise peptide delivery in oral, dermal, and topical applications. The collaborative team plans to undertake in vitro, ex vivo, and in silico studies to measure the absorption, bioavailability, and stability of specific peptides, such as BPC-157, GHK-Cu, and KPV. This will involve utilizing natural and safe permeation enhancers like Tremella fuciformis (Snow Mushroom) and DMSO to boost product efficacy and performance.
Focus areas for this research encompass:
- Pharmacokinetic (PK) and pharmacodynamic (PD) modeling to fine-tune formulation parameters and delivery profiles.
- Permeation and dissolution analyses conducted with skin and tissue-based membrane models.
- Formulation improvements utilizing natural excipients and botanical actives to boost bioavailability.
- Stability and analytical assessments to ensure product integrity and extend shelf life.
The findings from this research are expected to fortify Amino Innovations’ expanding intellectual property portfolio, elevate its regulatory standing, and expedite the development of new products within the nutraceutical and cosmeceutical sectors.
Dr. Neal Davies and Dr. Raimar Loebenberg commented, “We are enthusiastic about collaborating with Amino Innovations, a company dedicated to evidence-based, non-injectable natural peptide advancements. Our knowledge in biopharmaceutics, formulation science, and translational research will contribute to bringing validated peptide technologies to market that offer significant benefits in wellness and health science.”
Mr. Justin Kirkland, CSO and Co-Founder of Amino Innovations, noted, “This partnership provides us with access to top-tier research expertise and infrastructure. By producing pharmacokinetic and permeability data for essential peptide actives, we are fostering greater scientific transparency within the wellness industry.”
Mr. Pratap Sandhu, CEO of Pangea, further stated, “We are eager to support Amino Innovations as it continues to spearhead science-driven wellness innovation. This collaboration underscores our dedication to creating credible, research-backed products that uphold scientific integrity and fuel sustained growth.”
About Pangea Natural Foods Inc.
Pangea Natural Foods Inc. operates as a North American manufacturer focused on clean-label food items and inventive wellness solutions. Via its subsidiary, Amino Innovations, the Company provides advanced, non-injectable peptide delivery systems designed to aid recovery, cognitive function, and general well-being.
For the Board of Directors
“Pratap Sandhu”
Pratap Sandhu
CEO, Corporate Secretary and Director
+1 (604) 765-8069
media@pangeafood.com
Forward-Looking Statements
This press release includes forward-looking statements and information, as defined by relevant securities legislation. These statements pertain to future events or performance. Any statement not purely historical in nature may constitute a forward-looking statement or information. Such forward-looking statements and information are founded on specific key expectations and assumptions held by the Company’s management. Consequently, there is no guarantee that the acquisition or associated activities will conclude as anticipated or at all. While the Company’s management considers the expectations and assumptions underlying these forward-looking statements and information to be reasonable, readers are cautioned not to place excessive reliance on them, as there is no certainty they will prove accurate.